BioSpace News Archive

New technology innovations mark the company’s next milestones, and build on its pioneering history

SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer.

Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®

Khiron Life Sciences Corp. is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country.

The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer, led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences, were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology.

Innovent Biologics, Inc. announced that the study results for efficacy and safety of IBI305 compared with bevacizumab in advanced, first-line, non-squamous NSCLC patients were presented by poster at the 55th Annual Meeting of the American Society of Clinical Oncology.

CStone Pharmaceuticals announced that a new drug application for TIBSOVO® has been submitted by a third-party to the Taiwan Food and Drug Administration as the first to-be-approved treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.

Aimmune Therapeutics, Inc. presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase.